Quick Facts
  • wavy circle icon with check mark inside
    Sentinel Lymph Node Mapping
  • magnifying glass with heart icon
    Surgical Oncology
  • gender symbols interlocked icon
  • chat box with different language translations icon
  • pin location icon
    Primary Location:
    Wake Forest Baptist Health Comprehensive Cancer Center

Get to Know Dr. Edward A. Levine

Dr. Edward Levine is chief of surgical oncology services at the Wake Forest Baptist Medical Center Comprehensive Cancer Center in Winston-Salem, North Carolina.

He is recognized as a specialist in treating peritoneal surface malignancies, including peritoneal mesothelioma, a rare and aggressive cancer caused by asbestos exposure.

Levine is internationally recognized for the treatment combination of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy, often known as HIPEC, which has dramatically improved patient outcomes in recent years.

Clinical interests include stomach, breast, liver and esophageal cancers, along with melanoma and other gastrointestinal malignancies.

Levine also serves as a professor of surgical oncology, joining Wake Forest Baptist Medical Center in 1998, where he has been principal investigator in dozens of clinical trials designed to improve treatment protocols.

Specialties of Dr. Edward A. Levine

  • Mesothelioma
  • Gastrointestinal cancers
  • Appendiceal cancer
  • Melanoma
  • Research
  • Esophageal cancer
  • Sentinel lymph node mapping

Dr. Edward A. Levine’s Experience and Medical Education

  • Wake Forest Baptist Medical Center
  • Rosalind Franklin University of Medicine and Science
  • University of Illinois Hospital (Fellowship)
  • Michael Reese Hospital and Medical Center (Residency)
  • Finch University of Health Sciences, Chicago Medical School (M.D.)

Awards and Certifications

  • America’s Top Doctors for Cancer, Castle Connolly
  • American Board of Surgery
  • American Association of Clinical Oncology
  • Association for Academic Surgery
  • National Surgical Adjuvant Breast and Bowel Project

Mesothelioma Clinical Trials Under Edward A. Levine, M.D.

  • A phase I clinical trial studying the safety and potential efficacy of talimogene laherparepvec, an immunotherapy agent aimed at various peritoneal surface malignancies, including peritoneal mesothelioma.
Mesothelioma specialist speaking with a patient and his wife
Talk to a Doctor About Your Diagnosis
We can help you or a loved one get in contact with Dr. Levine and find the treatment that’s best for you.
Get Started Today

Helping to Advance Mesothelioma Treatment

Levine has helped pioneer a dramatic improvement in treating peritoneal mesothelioma cancer over the past two decades, through research and specialization in the HIPEC/cytoreductive surgery combination.

“This is a fascinating disease. And the truth is, we’re able to help most of these patients now,” he said. “We know a lot more about this disease than we did 10 year ago when it was absolutely uniform and we didn’t understand the subtypes of it.”

Too often, Levine hears people talk about the gloom and doom of this once untreatable disease, and of patients giving up before finding a specialty center with the latest expertise in treating it.

“The molecular underpinnings of this disease are only now being sorted out in detail,” he said. “To have a patient read something that is totally wrong, then get completely discouraged, just go home and die — when maybe there was treatment available — is frustrating. It shouldn’t be that way.”

Publications of Dr. Edward A. Levine

  • Binkley, P.F. & Levine, E. (2019, September). Organizational Strategies to Create a Burnout-Resistant Environment. Clinical Obstetrics Gynecology.
  • Enomoto, L.M. et al. (2019, July 31). Outcomes After Adjuvant Hyperthermic Intraperitoneal Chemotherapy for High-Risk Primary Appendiceal Neoplasms After Complete Resection. Annals of Surgical Oncology
  • Levine, E. (2019, March 27). Extensive Intraoperative Peritoneal Lavage to Prevent Metastases From Gastric Cancer: The Elegance of Simplicity. JAMA Surgery.